The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation

Background: Gemcitabine efficacy in pancreatic cancer is often impaired due to limited intracellular uptake and metabolic activation. Epi-drugs target gene expression patterns and represent a promising approach to reverse chemoresistance. In this study, we investigate the chemosensitizing effect of...

Descripción completa

Detalles Bibliográficos
Autores principales: Blaauboer, Amber, van Koetsveld, Peter M., Mustafa, Dana A. M., Dumas, Jasper, Dogan, Fadime, van Zwienen, Suzanne, van Eijck, Casper H. J., Hofland, Leo J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945828/
https://www.ncbi.nlm.nih.gov/pubmed/35327319
http://dx.doi.org/10.3390/biomedicines10030517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945828/
https://www.ncbi.nlm.nih.gov/pubmed/35327319
http://dx.doi.org/10.3390/biomedicines10030517

Ejemplares similares